-
- Avan Aihie Sayer
- Newcastle University AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, , Newcastle upon Tyne, UK
-
- Alfonso Cruz-Jentoft
- Hospital Universitario Ramón y Cajal Servicio de Geriatría, , Madrid, Spain
抄録
<jats:title>Abstract</jats:title> <jats:p>Sarcopenia is a skeletal muscle disorder that commonly occurs with advancing age as well as with a number of long-term conditions. Recognition in clinical practice is relatively recent but important because of the association between sarcopenia and a range of adverse effects on health including impaired mobility, increased morbidity and mortality. Originally characterised as loss of muscle mass, the definition has evolved to focus on loss of skeletal muscle function, particularly strength, through a number of international definitions such as that of the European Working Group on Sarcopenia in Older People most recently revised in 2019. Progress in the decades ahead is likely to be seen with regard to use of routine health data, prescription of resistance exercise, translation of biology and epidemiology into first in man studies for new treatments, and focus on sarcopenia in low and middle-income countries. Immediate next steps include the newly formed Global Leadership Initiative on Sarcopenia to develop international consensus on definition and diagnosis.</jats:p>
収録刊行物
-
- Age and Ageing
-
Age and Ageing 51 (10), 2022-10-01
Oxford University Press (OUP)
